Vertex’s Kalydeco obtains FDA approval to treat CF in children

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in children aged between two and five years.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news